BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) fell 1.6% on Friday . The stock traded as low as $2.35 and last traded at $2.39, with a volume of 61,233 shares traded. The stock had previously closed at $2.43.

Separately, Maxim Group set a $5.00 target price on BrainStorm Cell Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 11th.

The firm’s market cap is $44.58 million. The firm has a 50 day moving average of $2.48 and a 200 day moving average of $2.44.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings results on Thursday, August 11th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.13. On average, equities research analysts forecast that BrainStorm Cell Therapeutics Inc. will post ($0.34) earnings per share for the current fiscal year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.